

Interference Evaluation Heterophile, Thyroglobulin
Tumor Marker, Serum

Patient ID SA00173632	Patient Name TESTINGRNV, REPORTS ABE	Birth Date 1976-08-16	Sex M	Age 48
Order Number SA00173632	Client Order Number SA00173632	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 08 Jan 2025 07:03		

Interference Eval, Heterophile, TG

TG, Interference Interpretation

Result Name	Value	Unit	Reference Value	Performing Site
 TG, Interference Heterophile 	Detected			SDL

TG, Interpretation

Heterophile antibody interference was detected in the Beckman Access thyroglobulin (Tg) immunoassay (Thyroglobulin, Tumor Marker, S). The presence of thyroglobulin antibodies (TgAb) was not observed.

Evaluation consisted of pretreatment with commercial heterophile antibody blocking reagents, serial dilution of the sample, assessment for the presence of TgAb and testing on an alternate, mass spectrometry-based method (Tg-MS), which is believed to be unaffected by heterophile antibody interferences regardless of TgAb status.

When a heterophile antibody interference affecting the Beckman

1 SDL

Access Tg immunoassay is suspected, Beckman Access immunoassay measured Tg concentrations should not be used in clinical management. It is believed that Tg-MS measurements give accurate results in patients with or without heterophile antibody interferences regardless of TgAb status.

The presence of heterophile antibody interference in the Beckman Access Tg immunoassay is suspected when pretreatment results in a substantial reduction in Tg concentrations (>30%) upon pretreatment of the sample with heterophile antibody blocking reagents, a lack of linearity upon serial dilution, or a discrepancy in measured Tg concentration on the alternate method (Tg-MS).

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
SDL	Mayo Clinic Laboratories - Rochester Superior Drive	3050 Superior Drive NW, Rochester MN 55905	William G. Morice M.D. Ph.D.	24D1040592

Patient ID SA00173632	Patient Name TESTINGRNV, REPORTS ABE	Birth Date 1976-08-16	Sex M	Age 48
Order Number SA00173632	Client Order Number SA00173632	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 08 Jan 2025 07:03		

Result Name	Value	Unit	Reference Value	Performing Site
Thyroglobulin, Tumor Marker, S	40	ng/mL	≤ 33	SDL
Thyroglobulin (Tg) reference intervals are for patients with an intact thyroid and not for patients who have had surgery for thyroid cancer. Tg reference intervals in patients that have undergone thyroidectomy or any treatment for follicular thyroid cancer are dependent on the residual mass of the thyroid tissue after surgery. Tg results, regardless of concentration, should not be interpreted as absolute evidence for the presence or absence of papillary or follicular thyroid cancer. This result needs to be interpreted in the context of the clinical evaluation.				
Thyroglobulin Antibody, S	<1.8	IU/mL	<1.8	SDL
ADDITIONAL INFORMATION PLEASE NOTE: The given cutoff of <1.8 IU/mL is for the detection of potential thyroglobulin antibody (TgAb) interference in thyroglobulin immunoassays. A thyroglobulin antibody (TgAb) reference cutoff of <4.0 IU/mL may be more suitable for the evaluation of autoimmune thyroiditis. The thyroglobulin and thyroglobulin antibody testing methods are immunoenzymatic assays manufactured by Beckman Coulter Inc. and performed on the Unicel DXI 800. Values obtained from different assay methods or kits may be different and cannot be used interchangeably. The results cannot be interpreted as absolute evidence for the presence or absence of malignant disease.				

Result Name	Value	Unit	Reference Value	Performing Site
Thyroglobulin, Mass Spec., S	0.5	ng/mL	≤ 33	SDL

Thyroglobulin, Mass Spec., S

Interpretation

2 SDL

Thyroglobulin (Tg) reference intervals are for patients with an intact thyroid and not for patients who have had surgery for thyroid cancer. Tg reference intervals in patients that have undergone thyroidectomy or any treatment for follicular thyroid cancer are dependent on the residual mass of the thyroid tissue

after surgery. Tg results, regardless of concentration, should not be interpreted as absolute evidence for the presence or absence of papillary or follicular thyroid cancer. This result needs to be interpreted in the context of the clinical evaluation.

ADDITIONAL INFORMATION

This testing method is LC-MS/MS of an immunoaffinity purified tryptic digest of thyroglobulin. Values obtained from different

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
SDL	Mayo Clinic Laboratories - Rochester Superior Drive	3050 Superior Drive NW, Rochester MN 55905	William G. Morice M.D. Ph.D.	24D1040592



Patient ID SA00173632	Patient Name TESTINGRNV, REPORTS ABE	Birth Date 1976-08-16	Sex M	Age 48
Order Number SA00173632	Client Order Number SA00173632	Ordering Physician CLIENT,CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 08 Jan 2025 07:03		

assay methods or kits may be different and cannot be used interchangeably.

Received: 09 Jan 2025 14:33Reported: 09 Jan 2025 14:41

Laboratory Notes

- 1

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.
- 2

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
SDL	Mayo Clinic Laboratories - Rochester Superior Drive	3050 Superior Drive NW, Rochester MN 55905	William G. Morice M.D. Ph.D.	24D1040592